{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T00:15:15Z","timestamp":1792714515485,"version":"4.5.0"},"reference-count":34,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82072685"],"award-info":[{"award-number":["82072685"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100017555","name":"Zhejiang University Student Science and Technology Innovation Activity Plan","doi-asserted-by":"publisher","award":["2023R413059"],"award-info":[{"award-number":["2023R413059"]}],"id":[{"id":"10.13039\/501100017555","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002855","name":"Ministry of Science and Technology of the People's Republic of China","doi-asserted-by":"publisher","award":["2023YFE0118000"],"award-info":[{"award-number":["2023YFE0118000"]}],"id":[{"id":"10.13039\/501100002855","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Phytomedicine"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.phymed.2024.156022","type":"journal-article","created":{"date-parts":[[2024,9,7]],"date-time":"2024-09-07T18:49:14Z","timestamp":1725734954000},"page":"156022","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"special_numbering":"C","title":["Hypocrellin A against intrahepatic Cholangiocarcinoma via multi-target inhibition of the PI3K-AKT-mTOR, MAPK, and STAT3 signaling pathways"],"prefix":"10.1016","volume":"135","author":[{"given":"Bo","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiwen","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengmeng","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enguang","family":"Zou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ganglian","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiangqiao","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lushuang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuqian","family":"Gan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bicheng","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6067-6959","authenticated-orcid":false,"given":"Gang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lijun","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.phymed.2024.156022_bib0001","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1016\/S1470-2045(20)30157-1","article-title":"Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study","volume":"21","author":"Abou-Alfa","year":"2020","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.phymed.2024.156022_bib0002","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.biotechadv.2018.02.002","article-title":"Plants as sources of natural and recombinant anti-cancer agents","volume":"36","author":"Buyel","year":"2018","journal-title":"Biotechnol. Adv."},{"key":"10.1016\/j.phymed.2024.156022_bib0003","doi-asserted-by":"crossref","DOI":"10.1016\/j.compbiomed.2023.107612","article-title":"Predicting very early recurrence in intrahepatic cholangiocarcinoma after curative hepatectomy using machine learning radiomics based on CECT: a multi-institutional study","volume":"167","author":"Chen","year":"2023","journal-title":"Comput. Biol. Med."},{"key":"10.1016\/j.phymed.2024.156022_bib0004","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1007\/s00018-024-05162-x","article-title":"Role of the GLP2-Wnt1 axis in silicon-rich alkaline mineral water maintaining intestinal epithelium regeneration in piglets under early-life stress","volume":"81","author":"Chen","year":"2024","journal-title":"Cell Mol. Life Sci."},{"key":"10.1016\/j.phymed.2024.156022_bib0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2022.106580","article-title":"Metasilicate-based alkaline mineral water confers diarrhea resistance in maternally separated piglets via the microbiota-gut interaction","volume":"187","author":"Chen","year":"2023","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.phymed.2024.156022_bib0006","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.jare.2022.12.008","article-title":"Drinking alkaline mineral water confers diarrhea resistance in maternally separated piglets by maintaining intestinal epithelial regeneration via the brain-microbe-gut axis","volume":"52","author":"Chen","year":"2023","journal-title":"J. Adv. Res."},{"key":"10.1016\/j.phymed.2024.156022_bib0007","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.ctrv.2018.11.001","article-title":"Targeting the PI3K\/AKT\/mTOR pathway in biliary tract cancers: a review of current evidences and future perspectives","volume":"72","author":"Corti","year":"2019","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.phymed.2024.156022_bib0008","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2023.115513","article-title":"Targeting the STAT3 oncogenic pathway: cancer immunotherapy and drug repurposing","volume":"167","author":"Dong","year":"2023","journal-title":"Biomed. PharmacOther"},{"key":"10.1016\/j.phymed.2024.156022_bib0009","article-title":"Hypocrellins as photosensitizers for photodynamic therapy: a screening evaluation and pharmacokinetic study","volume":"37","author":"E P","year":"1996","journal-title":"Cancer Chemother Pharmacol."},{"key":"10.1016\/j.phymed.2024.156022_bib0010","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1186\/s12943-023-01827-6","article-title":"PI3K\/AKT\/mTOR signaling transduction pathway and targeted therapies in cancer","volume":"22","author":"Glaviano","year":"2023","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.phymed.2024.156022_bib0011","first-page":"4107","article-title":"Transferrin-modified nanostructured lipid carriers as multifunctional nanomedicine for codelivery of DNA and doxorubicin","volume":"9","author":"Han","year":"2014","journal-title":"Int. J. Nanomedicine"},{"key":"10.1016\/j.phymed.2024.156022_bib0012","article-title":"Research progress of natural small-molecule compounds related to tumor differentiation","volume":"27","author":"He","year":"2022","journal-title":"Molecules."},{"key":"10.1016\/j.phymed.2024.156022_bib0013","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1038\/s41571-023-00770-1","article-title":"Cholangiocarcinoma - novel biological insights and therapeutic strategies","volume":"20","author":"Ilyas","year":"2023","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.phymed.2024.156022_bib0014","article-title":"Gemox chemotherapy in combination with anti-PD1 antibody toripalimab and lenvatinib as first-line treatment for advanced intrahepatic cholangiocarcinoma: a phase 2 clinical trial","volume":"39","author":"Jian","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.phymed.2024.156022_bib0015","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1055\/s-2006-960121","article-title":"New perylenequinones from Shiraia bambusicola","volume":"57","author":"Kishi","year":"1991","journal-title":"Planta Med."},{"key":"10.1016\/j.phymed.2024.156022_bib0016","article-title":"Targeting MAPK signaling in cancer: mechanisms of drug resistance and sensitivity","volume":"21","author":"Lee","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.phymed.2024.156022_bib0017","doi-asserted-by":"crossref","first-page":"815","DOI":"10.3389\/fphar.2017.00815","article-title":"Transferrin-modified nanoparticles for photodynamic therapy enhance the antitumor efficacy of Hypocrellin A","volume":"8","author":"Lin","year":"2017","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.phymed.2024.156022_bib0018","doi-asserted-by":"crossref","first-page":"2350","DOI":"10.1158\/2159-8290.CD-21-1640","article-title":"Geospatial immune heterogeneity reflects the diverse tumor-immune interactions in intrahepatic cholangiocarcinoma","volume":"12","author":"Lin","year":"2022","journal-title":"Cancer Discov."},{"key":"10.1016\/j.phymed.2024.156022_bib0019","doi-asserted-by":"crossref","first-page":"e12894","DOI":"10.1111\/cpr.12894","article-title":"Cellular senescence and cancer: focusing on traditional Chinese medicine and natural products","volume":"53","author":"Liu","year":"2020","journal-title":"Cell Prolif."},{"key":"10.1016\/j.phymed.2024.156022_bib0020","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1038\/s41467-024-44795-1","article-title":"-Macro CD5L+ deteriorates CD8+T cells exhaustion and impairs combination of Gemcitabine-Oxaliplatin-Lenvatinib-anti-PD1 therapy in intrahepatic cholangiocarcinoma","volume":"15","author":"Lu","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.phymed.2024.156022_bib0021","doi-asserted-by":"crossref","first-page":"4450","DOI":"10.1128\/AAC.48.11.4450-4452.2004","article-title":"Antimicrobial and antileishmanial activities of hypocrellins A and B","volume":"48","author":"Ma","year":"2004","journal-title":"Antimicrob. Agents Chemother"},{"key":"10.1016\/j.phymed.2024.156022_bib0022","first-page":"198","article-title":"Advances in the treatment of intrahepatic cholangiocarcinoma: an overview of the current and future therapeutic landscape for clinicians","volume":"73","author":"Moris","year":"2023","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.phymed.2024.156022_bib0023","article-title":"The role of natural products and their multitargeted approach to treat solid cancer","volume":"11","author":"Muhammad","year":"2022","journal-title":"CellsCells"},{"key":"10.1016\/j.phymed.2024.156022_bib0024","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2022.40.4_suppl.378","article-title":"A phase 3 randomized, double-blind, placebo-controlled study of durvalumab in combination with gemcitabine plus cisplatin (GemCis) in patients (pts) with advanced biliary tract cancer (BTC): TOPAZ-1","volume":"40","author":"Oh","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.phymed.2024.156022_bib0025","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1001\/jamaoncol.2019.0270","article-title":"Gemcitabine, Cisplatin, and nab-paclitaxel for the treatment of advanced biliary tract cancers: a Phase 2 clinical trial","volume":"5","author":"Shroff","year":"2019","journal-title":"JAMa Oncol."},{"key":"10.1016\/j.phymed.2024.156022_bib0026","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1001\/jamasurg.2020.1973","article-title":"Very early recurrence after liver resection for intrahepatic cholangiocarcinoma: considering alternative treatment approaches","volume":"155","author":"Tsilimigras","year":"2020","journal-title":"JAMa Surg."},{"key":"10.1016\/j.phymed.2024.156022_bib0027","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.semcancer.2021.05.010","article-title":"RAF-MEK-ERK pathway in cancer evolution and treatment","volume":"85","author":"Ullah","year":"2022","journal-title":"Semin. Cancer Biol."},{"key":"10.1016\/j.phymed.2024.156022_bib0028","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1002\/hep.31803","article-title":"A transcriptomic signature for risk-stratification and recurrence prediction in intrahepatic cholangiocarcinoma","volume":"74","author":"Wada","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/j.phymed.2024.156022_bib0029","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.ejphar.2018.10.042","article-title":"Molecular evidence for better efficacy of hypocrellin A and oleanolic acid combination in suppression of HCC growth","volume":"842","author":"Wang","year":"2019","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.phymed.2024.156022_bib0030","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1002\/hep.32483","article-title":"Cellular heterogeneity and transcriptomic profiles during intrahepatic cholangiocarcinoma initiation and progression","volume":"76","author":"Wang","year":"2022","journal-title":"Hepatology"},{"key":"10.1016\/j.phymed.2024.156022_bib0031","doi-asserted-by":"crossref","DOI":"10.1016\/j.phymed.2022.153924","article-title":"Hypocrellin A exerts antitumor effects by inhibiting the FGFR1 signaling pathway in non-small cell lung cancer","volume":"97","author":"Yang","year":"2022","journal-title":"Phytomedicine"},{"key":"10.1016\/j.phymed.2024.156022_bib0032","first-page":"1376","article-title":"Exploration and validation of a novel ferroptosis-related gene signature predicting the prognosis of intrahepatic cholangiocarcinoma","volume":"54","author":"Yao","year":"2022","journal-title":"Acta Biochim. Biophys. Sin. (Shanghai)"},{"key":"10.1016\/j.phymed.2024.156022_bib0033","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.semcancer.2021.06.019","article-title":"Attacking the PI3K\/Akt\/mTOR signaling pathway for targeted therapeutic treatment in human cancer","volume":"85","author":"Yu","year":"2022","journal-title":"Semin. Cancer Biol."},{"key":"10.1016\/j.phymed.2024.156022_bib0034","first-page":"33","article-title":"Electronic spectra of hypocrellin A, B and their derivatives","author":"Z","year":"1990","journal-title":"Sci. China B"}],"container-title":["Phytomedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0944711324006792?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0944711324006792?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T09:05:55Z","timestamp":1762333555000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0944711324006792"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":34,"alternative-id":["S0944711324006792"],"URL":"https:\/\/doi.org\/10.1016\/j.phymed.2024.156022","relation":{},"ISSN":["0944-7113"],"issn-type":[{"value":"0944-7113","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Hypocrellin A against intrahepatic Cholangiocarcinoma via multi-target inhibition of the PI3K-AKT-mTOR, MAPK, and STAT3 signaling pathways","name":"articletitle","label":"Article Title"},{"value":"Phytomedicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.phymed.2024.156022","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier GmbH. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"156022"}}